

Lipocine to Present at the Canaccord Genuity 37th Annual Growth Conference

SALT LAKE CITY, Aug. 02, 2017 (GLOBE NEWSWIRE) -- [Lipocine Inc.](#) (NASDAQ:LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview at the Canaccord Genuity 37th Annual Growth Conference, being held August 9-10, 2017 at the InterContinental Boston Hotel in Boston, Massachusetts.

Presentation Details

Date: Wednesday, August 9

Time: 12:30 p.m. Eastern Time

Location: Montreal Room

Webcast: <http://wsw.com/webcast/canaccord26/lpcn>

About Lipocine

Lipocine Inc. is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes three development programs LPCN 1021, LPCN 1111 and LPCN 1107. LPCN 1021, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men. LPCN 1021 was well tolerated and met the primary efficacy end-points in Phase 3 testing with twice daily dosing. LPCN 1111, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing and is currently in Phase 2 testing. LPCN 1107, the potentially first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth, has been granted orphan drug designation by the FDA. An End of Phase 2 meeting with the FDA has been completed. For more information, please visit www.lipocine.com.

<https://ir.lipocine.com/Lipocine-to-Present-at-the-Canaccord-Genuity-37th-Annual-Growth-Conference>